| |
With three foreign trade zones, including the largest non-contiguous zone in the U.S., bioscience firms in Puerto Rico profit from affordable international trade. It's not what's next, it's where. Puerto Rico. .png)
|
|
Today’s Big NewsMay 9, 2024 |
|
Tuesday, May 14, 2024 | 9:30am ET / 6:30am PT This webinar dives into patient-derived organoids viewed as the gold standard in bridging the gap between the lab and the clinic. The oncology portfolio allows researchers to incorporate patient relevance at every stage of the drug development pipeline - from target discovery and hit identification to lead validation and optimization. Register now. 
|
|
| By Gabrielle Masson Novo Nordisk has penned a $600 million biobucks pact with Flagship-founded Metaphore Biotechnologies to develop up to two next-gen obesity treatments. |
|
|
|
By Nick Paul Taylor Novartis’ Entresto team has earned the ire of the PMCPA. For the third time in 12 months, the U.K. drug promotion watchdog has found the Swiss drugmaker’s actions have brought discredit upon the pharma industry. |
By Zoey Becker In a multi-year overhaul, the Japanese drugmaker plans to prioritize "organizational agility," procurement savings and tech efficiencies. It's all part of an effort to boost profit margins. |
By Fraiser Kansteiner Pfizer has proposed another round of staff reductions and role changes at legacy Seagen, this time hitting Seagen’s European headquarters in Switzerland, where 74 positions could be up for the chop. |
|
Tuesday, May 16, 2024 | 10 ET / 7am PT Clinical trials are shifting towards sustainability and efficiency, necessitating industry leaders to embrace innovative provisioned device solutions. This webinar reveals new approaches reshaping the clinical trial supply chain to mitigate carbon footprints and revolutionize device lifecycle management. Explore how proactive sustainability in device management can differentiate leading companies in life sciences innovation. 
|
|
By Conor Hale Following 12 company recalls and nearly 3,000 reported issues since January 2023, Getinge has now drawn more scrutiny from the FDA. |
By Kevin Dunleavy Five months out from their twin FDA approvals in sickle cell disease (SCD), who’s winning the race to treat patients with their respective gene therapies—bluebird bio or partners Vertex Pharmaceuticals and CRISPR Therapeutics? It’s not an easy question to answer. While Vertex leads in patient starts, bluebird has activated more treatment centers. |
By Nick Paul Taylor Takeda has taken an ax to its clinical-phase pipeline, hacking off midphase programs and early-stage prospects as part of a push to focus on its most promising prospects. |
By Andrea Park Healthcare marketing agency Vue Health has set its sights on a new executive hire to lead its digital transformation. |
By Annalee Armstrong Phil Gregory’s new gig looks a whole lot like his old gig. It’s just that, under the umbrella of Regeneron, things have gotten a bit bigger. |
By Fraiser Kansteiner While Merck & Co.’s Keytruda already boasts a pair of approvals to treat certain forms of endometrial cancer, a recent effort to prove the PD-1 inhibitor’s worth as a post-surgery add-on therapy in newly diagnosed patients has fallen short. |
By Nick Paul Taylor British biotechs have a new ally in their struggle to secure funding. Corporate affairs consultancy 5654 & Company has joined the fight, setting up a health and life sciences team to help businesses reach funders and communicate with industry, media and political stakeholders. |
By James Waldron Innovent has scored another phase 3 win for mazdutide, as the Eli Lilly drug showed its superiority to Trulicity when it came to glycemic control in patients with Type 2 diabetes. |
By Conor Hale According to the FDA, 224 injuries have been reported as of mid-April following potential interruptions to insulin delivery, out of more than 85,000 app downloads. |
By Nick Paul Taylor The need to stretch strained bank balances has hit pipelines once again. Rallybio and Monopar are the latest biotechs to rethink their spending, respectively stopping preclinical investment and pivoting to radiopharmaceuticals to stretch limited resources. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. |
|
|---|
|
|
|
Wednesday, May 22, 2024 | 11am ET / 8 am PT Learn GMP regulations in pharmaceutical storage at our upcoming webinar. Discover FDA requirements, including space validation, environmental controls, and risk mitigation. Explore services like aliquoting and cold chain transportation. Register now. 
|
|
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
